The global Engineered T Cells market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
Key companies engaged in the Engineered T Cells industry include Autolus Limited, Bellicum Pharmaceuticals, Cells Medica, Elli Lilly and Company, Gilead Sciences, Juno Therapeutics, Novartis, Oxford Biomedica and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Engineered T Cells were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Engineered T Cells market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Engineered T Cells market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Precision Bioscience
Redmile Group
Seeking Alpha
Unum Therapeutics
Segment by Type
Tumor Infiltrating Lymphocytes
T Cell Receptor {TCR}
Chimeric Antigen Receptor(CAR)
Segment by Application
Hospitals
Cancer Research Centers
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Engineered T Cells report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Engineered T Cells 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tumor Infiltrating Lymphocytes
1.2.3 T Cell Receptor {TCR}
1.2.4 Chimeric Antigen Receptor(CAR)
1.3 麻豆原创 by Application
1.3.1 Global Engineered T Cells 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Engineered T Cells 麻豆原创 Perspective (2018-2029)
2.2 Engineered T Cells Growth Trends by Region
2.2.1 Global Engineered T Cells 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Engineered T Cells Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Engineered T Cells Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Engineered T Cells 麻豆原创 Dynamics
2.3.1 Engineered T Cells Industry Trends
2.3.2 Engineered T Cells 麻豆原创 Drivers
2.3.3 Engineered T Cells 麻豆原创 Challenges
2.3.4 Engineered T Cells 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Engineered T Cells Players by Revenue
3.1.1 Global Top Engineered T Cells Players by Revenue (2018-2023)
3.1.2 Global Engineered T Cells Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Engineered T Cells 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Engineered T Cells Revenue
3.4 Global Engineered T Cells 麻豆原创 Concentration Ratio
3.4.1 Global Engineered T Cells 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Engineered T Cells Revenue in 2022
3.5 Engineered T Cells Key Players Head office and Area Served
3.6 Key Players Engineered T Cells Product Solution and Service
3.7 Date of Enter into Engineered T Cells 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Engineered T Cells Breakdown Data by Type
4.1 Global Engineered T Cells Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Engineered T Cells Forecasted 麻豆原创 Size by Type (2024-2029)
5 Engineered T Cells Breakdown Data by Application
5.1 Global Engineered T Cells Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Engineered T Cells Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Engineered T Cells 麻豆原创 Size (2018-2029)
6.2 North America Engineered T Cells 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Engineered T Cells 麻豆原创 Size by Country (2018-2023)
6.4 North America Engineered T Cells 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Engineered T Cells 麻豆原创 Size (2018-2029)
7.2 Europe Engineered T Cells 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Engineered T Cells 麻豆原创 Size by Country (2018-2023)
7.4 Europe Engineered T Cells 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Engineered T Cells 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Engineered T Cells 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Engineered T Cells 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Engineered T Cells 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Engineered T Cells 麻豆原创 Size (2018-2029)
9.2 Latin America Engineered T Cells 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Engineered T Cells 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Engineered T Cells 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Engineered T Cells 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Engineered T Cells 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Engineered T Cells 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Engineered T Cells 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Autolus Limited
11.1.1 Autolus Limited Company Detail
11.1.2 Autolus Limited Business Overview
11.1.3 Autolus Limited Engineered T Cells Introduction
11.1.4 Autolus Limited Revenue in Engineered T Cells Business (2018-2023)
11.1.5 Autolus Limited Recent Development
11.2 Bellicum Pharmaceuticals
11.2.1 Bellicum Pharmaceuticals Company Detail
11.2.2 Bellicum Pharmaceuticals Business Overview
11.2.3 Bellicum Pharmaceuticals Engineered T Cells Introduction
11.2.4 Bellicum Pharmaceuticals Revenue in Engineered T Cells Business (2018-2023)
11.2.5 Bellicum Pharmaceuticals Recent Development
11.3 Cells Medica
11.3.1 Cells Medica Company Detail
11.3.2 Cells Medica Business Overview
11.3.3 Cells Medica Engineered T Cells Introduction
11.3.4 Cells Medica Revenue in Engineered T Cells Business (2018-2023)
11.3.5 Cells Medica Recent Development
11.4 Elli Lilly and Company
11.4.1 Elli Lilly and Company Company Detail
11.4.2 Elli Lilly and Company Business Overview
11.4.3 Elli Lilly and Company Engineered T Cells Introduction
11.4.4 Elli Lilly and Company Revenue in Engineered T Cells Business (2018-2023)
11.4.5 Elli Lilly and Company Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Detail
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Engineered T Cells Introduction
11.5.4 Gilead Sciences Revenue in Engineered T Cells Business (2018-2023)
11.5.5 Gilead Sciences Recent Development
11.6 Juno Therapeutics
11.6.1 Juno Therapeutics Company Detail
11.6.2 Juno Therapeutics Business Overview
11.6.3 Juno Therapeutics Engineered T Cells Introduction
11.6.4 Juno Therapeutics Revenue in Engineered T Cells Business (2018-2023)
11.6.5 Juno Therapeutics Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Engineered T Cells Introduction
11.7.4 Novartis Revenue in Engineered T Cells Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Oxford Biomedica
11.8.1 Oxford Biomedica Company Detail
11.8.2 Oxford Biomedica Business Overview
11.8.3 Oxford Biomedica Engineered T Cells Introduction
11.8.4 Oxford Biomedica Revenue in Engineered T Cells Business (2018-2023)
11.8.5 Oxford Biomedica Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Engineered T Cells Introduction
11.9.4 Pfizer Revenue in Engineered T Cells Business (2018-2023)
11.9.5 Pfizer Recent Development
11.10 Precision Bioscience
11.10.1 Precision Bioscience Company Detail
11.10.2 Precision Bioscience Business Overview
11.10.3 Precision Bioscience Engineered T Cells Introduction
11.10.4 Precision Bioscience Revenue in Engineered T Cells Business (2018-2023)
11.10.5 Precision Bioscience Recent Development
11.11 Redmile Group
11.11.1 Redmile Group Company Detail
11.11.2 Redmile Group Business Overview
11.11.3 Redmile Group Engineered T Cells Introduction
11.11.4 Redmile Group Revenue in Engineered T Cells Business (2018-2023)
11.11.5 Redmile Group Recent Development
11.12 Seeking Alpha
11.12.1 Seeking Alpha Company Detail
11.12.2 Seeking Alpha Business Overview
11.12.3 Seeking Alpha Engineered T Cells Introduction
11.12.4 Seeking Alpha Revenue in Engineered T Cells Business (2018-2023)
11.12.5 Seeking Alpha Recent Development
11.13 Unum Therapeutics
11.13.1 Unum Therapeutics Company Detail
11.13.2 Unum Therapeutics Business Overview
11.13.3 Unum Therapeutics Engineered T Cells Introduction
11.13.4 Unum Therapeutics Revenue in Engineered T Cells Business (2018-2023)
11.13.5 Unum Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Precision Bioscience
Redmile Group
Seeking Alpha
Unum Therapeutics
听
听
*If Applicable.
